The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Defining the clinical course of multiple sclerosis: The 2013 revisions
Open accessAbstract
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PPMS (10-15% of patients) is characterised by an insidious, slowly progressive increase in neurological disability over time, usually without relapses.2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“At this time it is considered essential that a diagnosis of MS only be made in a patient who has symptoms suggestive of demyelination. 2”
From Diagnosis of multiple sclerosis: progress and challenges (2017) · cites this paper as [2]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Misdiagnosis of MS remains an issue in clinical practice. 8-11”
From Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (2018) · cites this paper as [10]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria
Polman, C. H., Reingold, S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., Fujihara, K., Havrdova, E., Hutchinson, M., Kappos, L., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22366 · Cited by 9,802
Self-citationDefining the clinical course of multiple sclerosis
LUBLIN, F. D., & Reingold, S. C. (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,762
Self-citationB-cell depletion with rituximab in relapsing-remitting multiple sclerosis
Hauser, S. L., Waubant, E., Arnold, D. L., Vollmer, T., Antel, J., Fox, R. J., Bar-Or, A., Panzara, M., Sarkar, N., Agarwal, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706383 · Cited by 2,439
Self-citationJacobs, L. D., Beck, R. W., Simon, J. H., Kinkel, R. P., Brownscheidle, C. M., Murray, T. J., Simonian, N. A., Slasor, P., & Sandrock, A. W. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431301 · Cited by 1,485
The Immunopathology of Multiple Sclerosis: An Overview
Lassmann, H., Brück, W., & Lucchinetti, C. F. (2007) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00064.x · Cited by 1,182
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, Ó., Hartung, H.-P., Seeldrayers, P., Sørensen, P. S., Rovaris, M., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04725-5 · Cited by 1,042
Self-citationProgressive multiple sclerosis: pathology and pathogenesis
Lassmann, H., van Horssen, J., & Mahad, D. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.168 · Cited by 1,033
Natural history of multiple sclerosis: a unifying concept
Confavreux, C., & Vukusic, S. (2006) · Brain · doi:10.1093/brain/awl007 · Cited by 901
Kappos, L., Polman, C. H., Freedman, M. S., Edan, G., Hartung, H., Miller, D., Montalbán, X., Barkhof, F., Bauer, L., Jakobs, P., et al. (2006) · Neurology · doi:10.1212/01.wnl.0000237641.33768.8d · Cited by 677
Self-citationIncidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome
Okuda, D. T., Mowry, E. M., Beheshtian, A., Waubant, E., Baranzini, S. E., Goodin, D. S., Hauser, S. L., & Pelletier, D. (2009) · Neurology · doi:10.1212/01.wnl.0000335764.14513.1a · Cited by 642
Self-citation
Cited by
Sorted by citations
Items 901–1,000 of 1,007
A much-needed focus on progression in multiple sclerosis
Thompson, A. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70330-8 · Cited by 23
Self-citationProgressive Multiple Sclerosis
Willis, M. A., & Fox, R. J. (2016) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000323 · Cited by 23
Self-citationKirov, I. I., Liu, S., Tal, A., Wu, W. E., Davitz, M. S., Babb, J. S., Rusinek, H., Herbert, J., & Gonen, O. (2017) · Human Brain Mapping · doi:10.1002/hbm.23647 · Cited by 23
Lorefice, L., Coghe, G., Fenu, G., Porta, M., Pilloni, G., Frau, J., Corona, F., Sechi, V., Barracciu, M. A., Marrosu, M. G., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8612-y · Cited by 23
Bonin, S., Zanotta, N., Sartori, A., Bratina, A., Manganotti, P., Trevisan, G., & Comar, M. (2017) · Immunological Investigations · doi:10.1080/08820139.2017.1405978 · Cited by 23
Navas, C., Torres-Duque, C. A., Muñoz-Cerón, J. F., Álvarez, C., García, J. R., Zarco, L. A., Vélez, L. A., Awad, C., & Castro, C. A. (2018) · Multiple Sclerosis Journal - Experimental Translational and Clinical · doi:10.1177/2055217317752202 · Cited by 23
An MRI evaluation of grey matter damage in African Americans with MS
Petracca, M., Zaaraoui, W., Cocozza, S., Vancea, R., Howard, J., Heinig, M. M., Fleysher, L., Oesingmann, N., Ranjeva, J., & Inglese, M. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.06.007 · Cited by 23
Self-citationForslin, Y., Bergendal, Å., Hashim, F., Martola, J., Shams, S., Wiberg, M. K., Fredrikson, S., & Granberg, T. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5815 · Cited by 23
Drug Treatment of Clinically Isolated Syndrome
Förster, M., Graf, J., Mareš, J., Aktaş, O., Hartung, H., & Kremer, D. (2019) · CNS Drugs · doi:10.1007/s40263-019-00647-x · Cited by 25
Diffusion basis spectrum imaging for identifying pathologies in MS subtypes
Shirani, A., Sun, P., Trinkaus, K. M., Perantie, D. C., George, A., Naismith, R. T., Schmidt, R. E., Song, S., & Cross, A. H. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50903 · Cited by 23
Standardization and digitization of clinical data in multiple sclerosis
D’Souza, M., Papadopoulou, A., Girardey, C., & Kappos, L. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-020-00448-7 · Cited by 23
Self-citationZailaie, S. A., Siddiqui, J. J., Saadi, R. M. A., Anbari, D. M., Alomari, A. S., & Cupler, E. (2021) · Immunological Investigations · doi:10.1080/08820139.2021.1887888 · Cited by 23
The Relationship Between Cognition and Cerebrovascular Reactivity: Implications for Task-Based fMRI
Williams, R. J., MacDonald, M. E., Mazerolle, E. L., & Pike, G. B. (2021) · Frontiers in Physics · doi:10.3389/fphy.2021.645249 · Cited by 23
Knowledge, attitude and practices regarding tuberculosis and dots among interns in delhi, India.
Rajpal, S., Mittal, A., Dhingra, V. K., Malhotra, R., Gupta, R., Malhotra, C., & Taneja, D. K. (2007) · PubMed · Cited by 23
Accelerated brain ageing and disability in multiple sclerosisPreprint
Cole, J. H., Raffel, J., Friede, T., Eshaghi, A., Brownlee, W. J., Chard, D., Stefano, N. D., Enzinger, C., Pirpamer, L., Filippi, M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/584888 · Cited by 24
Self-citationThe evaluation of MRI diffusion values of active demyelinating lesions in multiple sclerosis
Abdoli, M., Chakraborty, S., MacLean, H. J., & Freedman, M. S. (2016) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2016.09.006 · Cited by 22
Self-citationMultiplex assessment of cerebrospinal fluid biomarkers in multiple sclerosis
Mahler, M. R., Søndergaard, H. B., Buhelt, S., von Essen, M. R., Christensen, J. R., Enevold, C., & Sellebjerg, F. T. (2020) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2020.102391 · Cited by 22
Yeo, T., Sealey, M. A., Zhou, Y., Saldana, L., Loveless, S., Claridge, T. D. W., Robertson, N. P., DeLuca, G. C., Palace, J. A., Anthony, D. C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-69119-3 · Cited by 23
Becker, A., Abuazab, M., Schwiertz, A., Walter, S., Fassbender, K. C., Fousse, M., & Unger, M. M. (2021) · Autoimmunity Highlights · doi:10.1186/s13317-021-00149-1 · Cited by 23
Effect of BDNF Val66Met polymorphism on hippocampal subfields in multiple sclerosis patients
Meo, E. D., Portaccio, E., Prestipino, E., Nacmias, B., Bagnoli, S., Razzolini, L., Pastò, L., Niccolai, C., Goretti, B., Bellinvia, A., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01345-1 · Cited by 22
Sparaco, M., Miele, G., Lavorgna, L., Abbadessa, G., & Bonavita, S. (2022) · Neurological Sciences · doi:10.1007/s10072-022-05917-z · Cited by 24
Predictive MRI Biomarkers in MS—A Critical Review
Tiu, V. E., Enache, I. I., Panea, C., Tiu, C., & Popescu, B. O. (2022) · Medicina · doi:10.3390/medicina58030377 · Cited by 24
Vignesh, S. S., Munirathinam, B. R., Singh, N. K., & Krishna, R. (2022) · International Journal of Audiology · doi:10.1080/14992027.2022.2065548 · Cited by 23
Gold, R., Piani-Meier, D., Kappos, L., Bar‐Or, A., Vermersch, P., Giovannoni, G., Fox, R. J., Arnold, D. L., Benedict, R. H. B., Penner, I., et al. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11166-z · Cited by 22
Self-citationSchoeps, V. A., Graves, J., Stern, W. A., Zhang, L., Nourbakhsh, B., Mowry, E. M., Henry, R. G., & Waubant, E. L. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106941 · Cited by 22
Self-citationPutscher, E., Hecker, M., Fitzner, B., Boxberger, N., Schwartz, M., Koczan, D., Lorenz, P., & Zettl, U. K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.931831 · Cited by 22
Hejazi, S., Karwowski, W., Farahani, F. V., Marek, T., & Hancock, P. A. (2023) · Brain Sciences · doi:10.3390/brainsci13020246 · Cited by 23
Buchmann, A., Pirpamer, L., Pinter, D., Voortman, M. M., Helmlinger, B., Pichler, A., Maceski, A. M., Benkert, P., Bachmaier, G., Ropele, S., et al. (2023) · European Journal of Neurology · doi:10.1111/ene.15742 · Cited by 23
Maleki, A., Crispino, E., Italia, S. A., Salvatore, V. D., Chiacchio, M. A., Sips, F. L. P., Bursi, R., Russo, G. L., Maimone, D., & Pappalardo, F. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.05.020 · Cited by 22
The Impact of Aging on Multiple Sclerosis
Goyne, C., Fair, A. E., Sumowski, P., & Graves, J. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01333-2 · Cited by 24
The Impact of Microbiota–Immunity–Hormone Interactions on Autoimmune Diseases and Infection
Martinelli, S., Nannini, G., Cianchi, F., Coratti, F., & Amedei, A. (2024) · Biomedicines · doi:10.3390/biomedicines12030616 · Cited by 22
Hart, B. A. ‘., Dunham, J., Faber, B. W., Laman, J. D., van Horssen, J., Bauer, J., & Kap, Y. S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00804 · Cited by 22
Diffusion tensor imaging in multiple sclerosis at different final outcomes
Andersen, O., Hildeman, A., Longfils, M., Tedeholm, H., Skoog, B., Tian, W., Zhong, J., EKHOLM, S. E., Novakova, L., Runmarker, B., et al. (2017) · Acta Neurologica Scandinavica · doi:10.1111/ane.12797 · Cited by 22
Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study
Latino, P., Castelli, L., Prosperini, L., Marchetti, M. R., Pozzilli, C., & Giovannelli, M. (2017) · Neurological Sciences · doi:10.1007/s10072-017-3078-3 · Cited by 22
Self-citationGroen, K., Maltby, V. E., Lea, R. A., Sanders, K. A., Fink, J. L., Scott, R. J., Tajouri, L., & Lechner-Scott, J. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0365-7 · Cited by 21
Arevalo, O., Riascos, R., Rabiei, P., Kamali, A., & Nelson, F. M. (2018) · Journal of Computer Assisted Tomography · doi:10.1097/rct.0000000000000767 · Cited by 22
Lucchetta, R. C., Leonart, L. P., Becker, J., Pontarolo, R., Fernández-Llimós, F., & Wiens, A. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.06.036 · Cited by 22
Cocozza, S., Cosottini, M., Signori, A., Fleysher, L., Mendili, M. M. E., LUBLIN, F. D., Inglese, M., & Roccatagliata, L. (2020) · European Radiology · doi:10.1007/s00330-020-06803-y · Cited by 22
Self-citationBowen, J. D., Mehta, R. K., Pelletier, C. L., Tian, M., Noxon, V., Johnson, B. H., & Bonafede, M. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01367-1 · Cited by 22
Weathering the Storm: Harnessing the Resolution of Inflammation to Limit COVID-19 Pathogenesis
Silberberg, E., Filep, J. G., & Ariel, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.863449 · Cited by 22
Novel Drugs in a Pipeline for Progressive Multiple Sclerosis
Sapko, K., Jamróz-Wiśniewska, A., & Rejdak, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11123342 · Cited by 22
Immunological treatment of multiple sclerosis
Diebold, M., & Derfuss, T. J. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.04.016 · Cited by 22
Clinical utility of a molecular signature in inflammatory demyelinating disease
Pachner, A. R., DiSano, K. D., Royce, D. B., & Gilli, F. (2018) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000520 · Cited by 23
Autoimmune encephalomyelitis in NOD mice is not initially a progressive multiple sclerosis model
Baker, D., Nutma, E., O'Shea, H., Cooke, A., Orian, J. M., & Amor, S. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.792 · Cited by 21
Advancements in multiple sclerosis
Montague, T., Drummond, J., Ng, K., & Parratt, J. (2025) · Internal Medicine Journal · doi:10.1111/imj.70023 · Cited by 21
The natural history of early versus late disability accumulation in primary progressive MS
Koch, M. W., Greenfield, J., Javizian, O., Deighton, S., Wall, W., & Metz, L. M. (2014) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-307948 · Cited by 21
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis
Le, M. V., Malpas, C. B., Sharmin, S., Horáková, D., Havrdová, E., Trojano, M., Izquierdo, G., Eichau, S., Özakbaş, S., Lugaresi, A., et al. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520926955 · Cited by 21
Vascular endothelial dysfunction associated with severity in multiple sclerosis
Senzaki, K., Okada, Y., Ochi, H., Ochi, M., Takei, S., Miura, S., Igase, M., & Ohyagi, Y. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103135 · Cited by 22
The lived experience of uncertainty in everyday life with MS
Nissen, N., Lemche, J., Reestorff, C. M., Schmidt, M., Skjerbæk, A. G., Skovgaard, L., Stenager, E., Søgaard, I. G., & la Cour, K. (2021) · Disability and Rehabilitation · doi:10.1080/09638288.2021.1955302 · Cited by 21
A higher burden of multiple sclerosis genetic risk confers an earlier onset
Misicka, E., Davis, M. F., Kim, W., Brugger, S. W., Beales, J. T., Loomis, S. J., Bronson, P. G., & Briggs, F. B. S. (2021) · Multiple Sclerosis Journal · doi:10.1177/13524585211053155 · Cited by 21
Prevalence of trigeminal neuralgia in multiple sclerosis: A systematic review and meta-analysis
Houshi, S., Tavallaei, M. J., Barzegar, M., Afshari-Safavi, A., Vaheb, S., Mirmosayyeb, O., & Shaygannejad, V. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103472 · Cited by 21
Bonacchi, R., Meani, A., Pagani, E., Marchesi, O., Filippi, M., & Rocca, M. A. (2022) · Journal of Neurology · doi:10.1007/s00415-022-11021-1 · Cited by 23
Bachmann, P., Frahm, N., Debus, J. L., Mashhadiakbar, P., Langhorst, S. E., Streckenbach, B., Baldt, J., Heidler, F., Hecker, M., & Zettl, U. K. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030592 · Cited by 23
Plati, D. K., Tripoliti, E. E., Zelilidou, S. P., Vlachos, K. I., Konitsiotis, S., & Fotiadis, D. I. (2022) · Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc48229.2022.9871213 · Cited by 21
Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
Regner-Nelke, L., Pawlitzki, M., Willison, A., Rolfes, L., Oezalp, S.-H., Nelke, C., Kölsche, T., Korsen, M., Grothe, M., Groppa, S., et al. (2022) · Neurological Research and Practice · doi:10.1186/s42466-022-00219-3 · Cited by 21
Bientinesi, R., Gavi, F., Coluzzi, S., Nociti, V., Marturano, M., & Sacco, E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216572 · Cited by 21
Rosenstein, I., Axelsson, M., Novakova, L., Rasch, S., Blennow, K., Zetterberg, H., & Lycke, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1106028 · Cited by 22
Diffusion tensor imaging metrics associated with future disability in multiple sclerosis
López-Soley, E., Martínez‐Heras, E., Solana, E., Solanes, A., Raduà, J., Vivó, F., Prados, F., Sepúlveda, M., Cabrera‐Maqueda, J. M., Fonseca, E. G., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-30502-5 · Cited by 23
Mathematical analysis of neurological disorder under fractional order derivative
Khan, N. A., Ali, A., Ullah, A., & Khan, Z. A. (2023) · AIMS Mathematics · doi:10.3934/math.2023959 · Cited by 21
Biochemical biomarkers for multiple sclerosis
Maroto‐García, J., Martínez‐Escribano, A., Gil, V. D., Mañez, M., Mugueta, C., Varo, N., la Torre, A. G.-D., & Ruiz‐Galdón, M. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117471 · Cited by 25
Najafi, P., Hadizadeh, M., Cheong, J. P. G., Motl, R. W., Abdullah, S., Mohafez, H., & Poursadeghfard, M. (2023) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2023.105129 · Cited by 22
Lorefice, L., Ferraro, O. E., Fenu, G., Amato, M. P., Morra, V. B., Conte, A., Luca, G. D., Ferraro, D., Filippi, M., Gazzola, P., et al. (2024) · Journal of Neurology · doi:10.1007/s00415-023-12152-9 · Cited by 22
Self-citationDavarani, M. N., Darestani, A. A., Guillén, V., Azimi, H., Havadaragh, S. H., Hashemi, H., & Harirchian, M. H. (2024) · Scientific Reports · doi:10.1038/s41598-024-67130-6 · Cited by 22
Blackstone, J., Williams, T. E., Nicholas, J. M., Bordea, E., Angelis, F. D., Bianchi, A., Calvi, A., Doshi, A., John, N. A., Mangion, S. A., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-086414 · Cited by 22
Self-citationProgressive multiple sclerosis and mood disorders
Lorefice, L., Fenu, G., Trincas, G., Moro, M. F., Frau, J., Coghe, G., Cocco, E. E., Marrosu, M. G., & Carta, M. G. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2220-3 · Cited by 21
Neurodegeneration in multiple sclerosis is a process separate from inflammation: No
Hutchinson, M. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515612244 · Cited by 21
Dackovic, J. R., Pekmezovic, T. D., Mesaroš, Š., Dujmović, I., Stojsavljević, N., Martinović, V., & Drulovic, J. S. (2016) · Neurological Sciences · doi:10.1007/s10072-016-2610-1 · Cited by 21
Impairment of Smooth Pursuit as a Marker of Early Multiple Sclerosis
Lizak, N., Clough, M., Millist, L., Kalinčík, T., White, O. B., & Fielding, J. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00206 · Cited by 21
Montgomery, S., Maruszczak, M. J., Slater, D., Kusel, J., Nicholas, R. S., & Adlard, N. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1276070 · Cited by 21
Giacoppo, S., Bramanti, P., & Mazzon, E. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0460-z · Cited by 21
de Lemos, L. L. P., Guerra, A. A., Santos, M., Magliano, C. A. D. S., Diniz, I. M., Souza, K. M., Pereira, R. G., Álvares-Teodoro, J., Godman, B., Bennie, M., et al. (2017) · PharmacoEconomics · doi:10.1007/s40273-017-0579-0 · Cited by 21
Pinzón, N. E., Brevé, J. J. P., Bol, J. G. J. M., Drukarch, B., Baron, W., & van Dam, A. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1031-2 · Cited by 22
Cristiano, E., Alonso, R. N., Pinheiro, A. A., Bacile, E. A. B., Balbuena, M. E., Ballario, C., Barboza, A. G., Bestoso, S., Burgos, M., Cáceres, F., et al. (2018) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2018.01.004 · Cited by 21
Changes in structural network are associated with cortical demyelination in early multiple sclerosis
Mangeat, G., Badji, A., Ouellette, R., Treaba, C. A., Herranz, E., Granberg, T., Louapre, C., Stikov, N., Sloane, J. A., Bellec, P., et al. (2018) · Human Brain Mapping · doi:10.1002/hbm.23993 · Cited by 21
Hartung, H., Graf, J., & Kremer, D. (2019) · Journal of Neurology · doi:10.1007/s00415-018-09169-w · Cited by 21
Lorefice, L., Murgia, F., Fenu, G., Frau, J., Coghe, G., Murru, M. R., Tranquilli, S., Visconti, A., Marrosu, M. G., Atzori, L., et al. (2019) · Neurotherapeutics · doi:10.1007/s13311-019-00721-8 · Cited by 21
Emerging small-molecule treatments for multiple sclerosis: focus on B cells
Gregson, A. M., Thompson, K. K., Tsirka, S. E., & Selwood, D. L. (2019) · F1000Research · doi:10.12688/f1000research.16495.1 · Cited by 20
High levels of serum soluble TWEAK are associated with neuroinflammation during multiple sclerosis
Maarouf, A., Stephan, D., Ranjeva, M., Ranjeva, J., Pelletier, J., Audoin, B., Khrestchatisky, M., & Desplat‐Jégo, S. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1789-3 · Cited by 21
Navigating choice in multiple sclerosis management
Linker, R. A., & Chan, A. (2019) · Neurological Research and Practice · doi:10.1186/s42466-019-0005-5 · Cited by 21
Solari, A., Giovannetti, A. M., Giordano, A., Tortorella, C., Clerici, V. T., Brichetto, G., Granella, F., Lugaresi, A., Patti, F., Salvetti, M., et al. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00916 · Cited by 21
Impact of multiple sclerosis phenotypes on burden of disease in Finland
Purmonen, T. T., Hakkarainen, T., Tervomaa, M., & Ruutiainen, J. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1682004 · Cited by 21
de la Peña, M. J., Peño, I. C., García, P. G., Gavilán, M. L., Malpica, N., Alonso, M. R., González, R. V. A., & de Vega, V. M. (2019) · Acta Radiologica Open · doi:10.1177/2058460119894214 · Cited by 21
Jakimovski, D., Bergsland, N., Dwyer, M. G., Hagemeier, J., Ramasamy, D. P., Szigeti, K., Guttuso, T. J., Lichter, D. G., Hojnacki, D. W., Weinstock‐Guttman, B., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.02.002 · Cited by 21
Experimental Models of Neuroimmunological Disorders: A Review
da Silva, A. P. B., Silva, R. B. M., Goi, L. D. S., Molina, R. D., Machado, D. C., & Sato, D. K. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00389 · Cited by 22
Storelli, L., Pagani, E., Preziosa, P., Filippi, M., & Rocca, M. A. (2020) · Multiple Sclerosis Journal · doi:10.1177/1352458520938999 · Cited by 22
Rituximab for people with multiple sclerosis
Filippini, G., Kruja, J., & Giovane, C. D. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013874.pub2 · Cited by 22
Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study
Bucello, S., Annovazzi, P. O. L., Ragonese, P., Altieri, M., Barcella, V., Bergamaschi, R., Bianchi, A., Borriello, G., Buscarinu, M. C., Callari, G., et al. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10455-3 · Cited by 22
Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis
Huygens, S. A., & Versteegh, M. (2021) · Value in Health · doi:10.1016/j.jval.2021.05.020 · Cited by 21
Trajectory of MS disease course for men and women over three eras
Hum, S., Lapierre, Y., Scott, S. C., Duquette, P., & Mayo, N. E. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458516655478 · Cited by 21
Soundy, A., Roskell, C., Adams, R. L., Elder, T. J., & Dawes, H. (2016) · Open Journal of Therapy and Rehabilitation · doi:10.4236/ojtr.2016.44018 · Cited by 23
Bodini, B., Branzoli, F., Poirion, É., García-Lorenzo, D., Didier, M., Maillart, É., Socha, J., Bera, G. C., Lubetzki, C., Ronen, I., et al. (2017) · Multiple Sclerosis Journal · doi:10.1177/1352458517698249 · Cited by 23
Self-citationVisual Pathway Measures are Associated with Neuropsychological Function in Multiple Sclerosis
Nguyen, J. V., Rothman, A., Fitzgerald, K. C., Whetstone, A., Syc‐Mazurek, S. B., Aquino, J. J., Balcer, L. J., Frohman, E. M., Frohman, T. C., Crainiceanu, C. M., et al. (2018) · Current Eye Research · doi:10.1080/02713683.2018.1459730 · Cited by 22
Self-citationPharmacological management of depression in patients with multiple sclerosis
Carta, M. G., Paribello, P., Anastasia, A., Berardis, D. D., Nardi, A. E., & Fornaro, M. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1516207 · Cited by 21
Animal models of olfactory dysfunction in neurodegenerative diseases
Prediger, R. D., Schamne, M. G., Sampaio, T. B., Moreira, E. L. G., & Rial, D. (2019) · Handbook of clinical neurology · doi:10.1016/b978-0-444-63855-7.00024-1 · Cited by 21
Berger, T., & Stüve, O. (2019) · Neurology · doi:10.1212/wnl.0000000000007022 · Cited by 24
Self-citationFunctional muscle balance assessment in multiple sclerosis
Neamțu, M. C., Neamţu, O. M., Rusu, M. R., Marin, M. I., & Rusu, L. (2019) · Journal of Back and Musculoskeletal Rehabilitation · doi:10.3233/bmr-191518 · Cited by 20
Chataway, J., Williams, T. E., Blackstone, J., John, N. A., Braisher, M., Angelis, F. D., Bianchi, A., Calvi, A., Doshi, A., Mangion, S. A., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01039-6 · Cited by 23
Self-citationCommon Diseases in Clinical Cohorts — Not Always What They Seem
Rahimov, F., Jacobs, B. M., Lee, J. S., Mahi, N. A., Blumenfeld, A. M., Alsheikh, A. J., Abbasi, A., Reppell, M., Pivorunas, V. L., Sigurðsson, H. J., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2405459 · Cited by 20
Combined magnetic resonance imaging and serum analysis reveals distinct multiple sclerosis types
Willard, C., Puglisi, L., Ravì, D., Dmitrieva, M., Mattiesing, R. M., Barkhof, F., Alexander, D. C., Harlow, D. E., Piani-Meier, D., & Eshaghi, A. (2025) · Brain · doi:10.1093/brain/awaf331 · Cited by 21
Self-citationPharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis
Nandoskar, A., Raffel, J., Scalfari, A., Friede, T., & Nicholas, R. S. (2017) · Drugs · doi:10.1007/s40265-017-0726-0 · Cited by 21
Metadata
- Authors
- Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., Bebo, B., Calabresi, P. A., Clanet, M., Comi, G., Fox, R. J., Freedman, M. S., Goodman, A. D., Inglese, M., Kappos, L., Kieseier, B. C., Lincoln, J. A., Lubetzki, C., Miller, A. E., Montalban, X., O'Connor, P. W., Petkau, J., Pozzilli, C., Rudick, R. A., Sormani, M. P., Stüve, O., Waubant, E., & Polman, C. H.
- Affiliations
- Cleveland Clinic (US)
- From the Corinne Goldsmith Dickenson Center for Multiple Sclerosis (F.D.L., A.E.M.), Icahn School of Medicine at Mount Sinai, New York, NY; Scientific and Clinical Review Associates, LLC (S.C.R.), Salisbury, CT; The Mellen Center for MS Treatment and Research (J.A.C., R.J.F., R.A.R.), Cleveland Clinic, OH; the Department of Biostatistics (G.R.C.), University of Alabama at Birmingham; the Danish Multiple Sclerosis Center (P.S.S.), Department of Neurology, Copenhagen University Hospital Rigshospitalet...
- Corresponding author
- Lublin, Fred D.
- ORCID
- Lublin, Fred D.
- Reingold, Stephen C.
- Cohen, Jeffrey A.
- Cutter, Gary R.
- Sørensen, Per Soelberg
- Thompson, Alan J.
- Wolinsky, Jerry S.
- Balcer, Laura J.
- Banwell, Brenda
- Barkhof, Frederik
- Bebo, Bruce
- Calabresi, Peter A.
- Comi, Giancarlo
- Fox, Robert J.
- Goodman, Andrew D.
- Inglese, Matilde
- Kappos, Ludwig
- Lincoln, John A.
- Lubetzki, Catherine
- Miller, Aaron E.
- O'Connor, Paul W.
- Pozzilli, Carlo
- Rudick, Richard A.
- Sormani, Maria Pia
- Stüve, Olaf
- Waubant, Emmanuelle
- Polman, Chris H.
- Venue
- Neurology
- Published
- 2014-07-15
- Volume
- 83
- Issue
- 3
- Pages
- 278-286
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC4117366
- OpenAlex
- W2105206040
- Cited by
- 3,177
- References
- 32
- Citations by year
- 2026: 229 · 2025: 266 · 2024: 335 · 2023: 308 · 2022: 333 · 2021: 333 · 2020: 298 · 2019: 274 · 2018: 232 · 2017: 236 · 2016: 193 · 2015: 105 · 2014: 27
- FWCI
- 139.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Neurology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Multiple Sclerosis Society
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Cleveland Clinic
- Novartis Pharmaceuticals Corporation
- University of Alabama at Birmingham
- European Committee for Treatment and Research in Multiple Sclerosis
- Wellcome Trust
- Ironwood Pharmaceuticals, Incorporated
- University of Alabama
- Myelin Repair Foundation
- University of Texas Health Science Center at Houston
- GW Pharmaceuticals
- Acorda Therapeutics
- Prothena
- Glenmark Pharmaceuticals
- National Institute for Health and Care Research
- Multiple Sclerosis Society
- University of Cambridge
- European Commission
- Bayer HealthCare
- Wolfson Foundation
- National Research Foundation
- Eisai
- Multiple Sclerosis International Federation
- Schweizerische Multiple Sklerose Gesellschaft
- Sun Pharma
- Serono Symposia International Foundation
- Grifols
- National Institutes of Health
- Genentech
- EMD Serono
- Bayer Canada
- Sanofi Genzyme
- Canadian Institutes of Health Research
- Natural Sciences and Engineering Research Council of Canada
- Medical Research Council
- National Heart, Lung, and Blood Institute
- National Institute of Neurological Disorders and Stroke
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Keywords
- multiple sclerosis, clinical course, disease phenotypes, clinical trial design, relapse rate, disease activity, disease progression, MRI findings, biomarkers
- MeSH terms
- Clinical Trials as Topic, Humans, Multiple Sclerosis, Societies, Medical, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
